{"id":86512,"date":"2012-02-03T17:09:44","date_gmt":"2012-02-03T16:09:44","guid":{"rendered":"http:\/\/testcase.r-biopharm.com\/?p=9"},"modified":"2018-11-09T15:47:02","modified_gmt":"2018-11-09T14:47:02","slug":"ridaline-helicobacter-igg-iga","status":"publish","type":"post","link":"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/","title":{"rendered":"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG &#038; IgA  (de)"},"content":{"rendered":"<p><strong>Zuverl\u00e4ssige Differenzierung von humanen IgG- und IgA-Antik\u00f6rpern gegen Helicobacter pylori-St\u00e4mme Typ I und II<\/strong><!--more--><\/p>\n<p>Mehr als die H\u00e4lfte der Weltbev\u00f6lkerung ist mit dem gramnegativen, spiralf\u00f6rmigen Bakterium Helicobacter pylori (H. pylori) infiziert. Eine H. pylori-Infektion wird mit einem erh\u00f6hten Risiko f\u00fcr Magenkarzinome sowie mit fast allen Magenulzera in Verbindung gebracht.<\/p>\n<p>Wichtig bei der H. pylori-Diagnostik ist die Unterscheidung der H. pylori-St\u00e4mme Typ I und II. So f\u00fchrenInfektionen des Typ I-Stammes, die positiv f\u00fcr die Virulenzfaktoren CagA und VacA sind, zu einem ernsthafteren Krankheitsverlauf als die Infektionen mit dem Typ II-Stamm. R-Biopharm bietet nun, zus\u00e4tzlich zu den beiden ELISA-Testsystemen <a href=\"http:\/\/www.r-biopharm.com\/de\/produkte\/klinische-diagnostik\/antikoerpernachweis\/bakterien\">RIDASCREEN\u00ae Helicobacter IgG<\/a> und RIDASCREEN\u00ae Helicobacter IgA, zwei neue Lineblot-Testsysteme f\u00fcr die Detektion von H. pylori an. RIDA\u00aeLINE Helicobacter IgG und RIDA\u00aeLINE Helicobacter IgA ersetzen die bisherigen Western Blot-Testsysteme RIDA\u00aeBLOT Helicobacter IgG und RIDA\u00aeBLOT Helicobacter IgA.<\/p>\n<p>Im Vergleich zu den bisherigen Western Blots erm\u00f6glichen die beiden neuen RIDA\u00aeLINE Tests aufgrund der Auswahl spezifischer rekombinanter Antigene einen zuverl\u00e4ssigen, differenzierten Nachweis der H. pylori-St\u00e4mme vom Typ I und II. Neben h\u00f6chster Sensitivit\u00e4t und Spezifit\u00e4t erm\u00f6glichen leicht ablesbare Banden eine einfache und klare Interpretation. Mit der Kombination aus IgG- und IgA-ELISAs und den entsprechenden Line Blots bietet R-Biopharm nun ein umfangreiches Angebot f\u00fcr den Nachweis von sowohl akuten als auch chronischen H. pylori-Infektionen an.<\/p>\n<p>Der neue RIDA\u00aeLINE Helicobacter IgG ist unter der Artikelnummer LB2323 und RIDA\u00aeLINE Helicobacter IgA unter LB2313 erh\u00e4ltlich.<\/p>\n<h3>Products for the specific detection of Helicobacter pylori:<\/h3>\n<table class=\"wp-table-reloaded\">\n<caption style=\"caption-side: bottom; text-align: left; border: none; background: none;\">\u00a0<\/caption>\n<thead>\n<tr class=\"row-1 odd\">\n<th class=\"column-1\">Products<\/th>\n<th class=\"column-2\">Assays<\/th>\n<th class=\"column-3\">Art. No.<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr class=\"row-2 even\">\n<td class=\"column-1 colspan-3\" colspan=\"3\"><strong>RIDASCREEN\u00ae &#8211; Enzyme immunoassays for antibody detection<\/strong><\/td>\n<\/tr>\n<tr class=\"row-3 odd\">\n<td class=\"column-1\">RIDASCREEN\u00ae &#8211; Helicobacter lgG<\/td>\n<td class=\"column-2\">96<\/td>\n<td class=\"column-3\">K2321<\/td>\n<\/tr>\n<tr class=\"row-4 even\">\n<td class=\"column-1\">RIDASCREEN\u00ae &#8211; Helicobacter lgA<\/td>\n<td class=\"column-2\">96<\/td>\n<td class=\"column-3\">K2311<\/td>\n<\/tr>\n<tr class=\"row-5 odd\">\n<td class=\"column-1 colspan-3\" colspan=\"3\"><strong>RIDA\u00aeLINE &#8211; Line blots<\/strong><\/td>\n<\/tr>\n<tr class=\"row-6 even\">\n<td class=\"column-1\">RIDA\u00aeLINE Helicobacter lgG<\/td>\n<td class=\"column-2\">20<\/td>\n<td class=\"column-3\">LB2323<\/td>\n<\/tr>\n<tr class=\"row-7 odd\">\n<td class=\"column-1\">RIDA\u00aeLINE Helicobacter lgA<\/td>\n<td class=\"column-2\">20<\/td>\n<td class=\"column-3\">LB2313<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zuverl\u00e4ssige Differenzierung von humanen IgG- und IgA-Antik\u00f6rpern gegen Helicobacter pylori-St\u00e4mme Typ I und II<\/p>\n","protected":false},"author":324,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG &amp; IgA (de) - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG &amp; IgA (de) - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"og:description\" content=\"Zuverl\u00e4ssige Differenzierung von humanen IgG- und IgA-Antik\u00f6rpern gegen Helicobacter pylori-St\u00e4mme Typ I und II\" \/>\n<meta property=\"og:url\" content=\"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/\" \/>\n<meta property=\"og:site_name\" content=\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"article:published_time\" content=\"2012-02-03T16:09:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-11-09T14:47:02+00:00\" \/>\n<meta name=\"author\" content=\"aschlereth\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"aschlereth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/\",\"url\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/\",\"name\":\"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG & IgA (de) - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"isPartOf\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\"},\"datePublished\":\"2012-02-03T16:09:44+00:00\",\"dateModified\":\"2018-11-09T14:47:02+00:00\",\"author\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\"},\"breadcrumb\":{\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/devclinical.r-biopharm.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG &#038; IgA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\",\"url\":\"https:\/\/devdevclinical.r-biopharm.com\/\",\"name\":\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed\",\"name\":\"aschlereth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/17b133547cbc94dca425be27f132185b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/17b133547cbc94dca425be27f132185b?s=96&d=mm&r=g\",\"caption\":\"aschlereth\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG & IgA (de) - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"de_DE","og_type":"article","og_title":"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG & IgA (de) - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","og_description":"Zuverl\u00e4ssige Differenzierung von humanen IgG- und IgA-Antik\u00f6rpern gegen Helicobacter pylori-St\u00e4mme Typ I und II","og_url":"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/","og_site_name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","article_published_time":"2012-02-03T16:09:44+00:00","article_modified_time":"2018-11-09T14:47:02+00:00","author":"aschlereth","twitter_misc":{"Verfasst von":"aschlereth","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/","url":"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/","name":"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG & IgA (de) - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","isPartOf":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#website"},"datePublished":"2012-02-03T16:09:44+00:00","dateModified":"2018-11-09T14:47:02+00:00","author":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed"},"breadcrumb":{"@id":"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/devclinical.r-biopharm.com\/de\/news\/ridaline-helicobacter-igg-iga\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/devclinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Neue Streifen-Immunoassays RIDA\u00aeLINE Helicobacter IgG &#038; IgA"}]},{"@type":"WebSite","@id":"https:\/\/devdevclinical.r-biopharm.com\/#website","url":"https:\/\/devdevclinical.r-biopharm.com\/","name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/9ad371ec418286e0043ce49d29ff10ed","name":"aschlereth","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/17b133547cbc94dca425be27f132185b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/17b133547cbc94dca425be27f132185b?s=96&d=mm&r=g","caption":"aschlereth"}}]}},"_links":{"self":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/86512"}],"collection":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/324"}],"replies":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=86512"}],"version-history":[{"count":1,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/86512\/revisions"}],"predecessor-version":[{"id":95242,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/86512\/revisions\/95242"}],"wp:attachment":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=86512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=86512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=86512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}